Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sartorius Officially Opens Production Facility for Bioreactors in Guxhagen, Germany

Published: Saturday, September 15, 2012
Last Updated: Saturday, September 15, 2012
Bookmark and Share
18 million euros invested in the expansion of manufacturing capacity.

Sartorius has formally opened its new plant in Guxhagen in northern Hesse for the manufacture of bioreactors.

After approximately one year of construction, the new building was officially dedicated in the presence of the prime minister of the state government of Hesse, Volker Bouffier; the mayor of the community of Guxhagen, Edgar Slawik; as well as numerous guests from the local political and business community.

Approximately 18 million euros were invested in the plant at which Sartorius now manufactures bioreactors and further production equipment for customers in the biopharmaceutical industry.

Covering a total area of nearly 10,000 square feet, the new building complex provides space for a high-tech manufacturing hall and offices for around 240 employees.

The building owner is Robos GmbH, from which Sartorius has rented the premises in a long-term lease.

By opening this new site in Guxhagen, Sartorius has moved from its former bioreactor production facility in Melsungen, Germany, where it had reached maximum capacity limits.

Prime Minister Volker Bouffier stated after a tour of the plant, "By deciding to build a new production facility just a few kilometers away from Melsungen, Sartorius AG has reinforced its close ties with northern Hesse. At the same time, this decision also underscores the advantages of the business location of the State of Hesse, according to him: "We offer companies an excellent infrastructure and intentionally promote the regional economy so that innovative medium-sized companies will invest in and stay with us," said the Prime Minister.

"The new plant enables us to substantially enhance our manufacturing processes and creates additional capacity for us in view of the rising demand for biopharmaceutical production equipment. As a result, we are optimally prepared for further expansion, especially for single-use bioreactors," said Joachim Kreuzburg, the CEO and Executive Board Chairman of Sartorius AG.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sartorius Acquires Cellca
Sartorius Stedim Biotech (SSB) acquired Cellca, a Laupheim, Germany-based company that specializes in cell line and process development.
Friday, July 03, 2015
TAP Biosystems and Merck & Co., Inc. Double Triumph at BPI 2014 Awards
“Best Collaboration” and “Best Technology Application — Upstream” Awards acknowledges ambr250 mini bioreactor system as an exceptional technology.
Monday, October 27, 2014
Sartorius Appoints Internationally Experienced Laboratory Manager
Michael Melingo to succeed Dominique Baly in the Sartorius lab business.
Friday, January 31, 2014
Sartorius Officially Opens New Filter and Aseptic Bag Production Facility in Puerto Rico
Sixteen million euros invested in the expansion of production capacity.
Wednesday, June 27, 2012
Scientific News
NIH Launches Early-Stage Yellow Fever Vaccine Trial
Researchers at NIH have begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!